$OVID

$2.26 +$0.10 (4.87%) Close

$OVID Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 195.3M shares outstanding

Who owns OVID?

By type of holder

Institutions 75.2% Insiders 6.7% Everyone else 18.1%

Concentration Top 10 holders own 51.2%

Jupiter Topco LLC 10.6% · Eventide Asset Management, LLC 6.1%

Institutional ownership

75.2%

+21.4 pts vs last qtr

Institutional holders

129

+26 vs last qtr

Net shares bought

+41.9M

by institutions in Q2 2026

New / sold out

46 / 20

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Jupiter Topco LLC NEW +20.7M
BlackRock, Inc. +9.3M

Biggest sellers in Q2 2026

Janus Henderson Group PLC SOLD OUT −10.7M
Saturn V Capital Management LP −3.5M

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Ovid Therapeutics Inc. in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2020–FY2023

+20.8%

+6.49% a year

Each share's claim on the business

−17.2%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $26.4M

over 4 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years25% 3–5 years0% 1–3 years17% Under 1 year58%

Quarterly turnover

48.0%

of institutional shares changed hands

Top 10 managers, median time held

1.5 years

Super Investors

Investment managers reporting OVID on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
JT Jupiter Topco LLC	20.7M	10.62%	NEW	Q2 '26	0.0%
Shares held by quarter Peak holding20.7M (Q2'26) Change over 8 quarters+20.7M Share of the company10.620% Jupiter Topco LLC's full portfolio →
EA Eventide Asset Management, LLC	11.8M	6.05%	+1.9M (+19.1%)	Q4 '25	0.4%
Shares held by quarter Peak holding11.8M (Q2'26) Change over 8 quarters+11.8M Share of the company6.050% Eventide Asset Management, LLC's full portfolio →

Jupiter Topco LLC

20.7M

% of company

10.62%

Change vs last qtr

NEW

Held since

Q2 '26

Eventide Asset Management, LLC

11.8M

% of company

6.05%

Change vs last qtr

+1.9M (+19.1%)

Held since

Q4 '25

28 more super investors behind a free account

See every manager holding Ovid Therapeutics Inc., how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting OVID on Form N-PORT; together they hold 15.2% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$15.2M	5.7M	2.89%	0.00%	June 30, 2026
SS State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR Series Trust	$13.2M	4.9M	2.52%	0.12%	June 30, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$15.2M

% of company

2.89%

% of the fund

0.00%

As of

June 30, 2026

State Street(R) SPDR(R) S&P(R) Biotech ETF

SPDR Series Trust

Position value

$13.2M

% of company

2.52%

% of the fund

0.12%

As of

June 30, 2026

23 more funds behind a free account

See every fund holding Ovid Therapeutics Inc. and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
LJ Levin Jeremy M Insider	3.8M	1.93%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company1.930% Levin Jeremy M's insider activity →
PS Papadopoulos Stelios Insider	217.6K	0.11%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company0.110% Papadopoulos Stelios's insider activity →

Levin Jeremy M

Insider

3.8M

% of company

1.93%

Change vs last qtr

—

Held since

—

Papadopoulos Stelios

Insider

217.6K

% of company

0.11%

Change vs last qtr

—

Held since

—

5 more holders behind a free account

See every insider and 5%+ holder of Ovid Therapeutics Inc..

Comments